In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Modafinil, a wake-promoting drug used to treat narcolepsy, is a dopamine transporter inhibitor and is said to have very low abuse liability; this, however, is still up for debate. We conducted a dopamine transporter (DAT) occupancy study with modafinil (200 or 300 mg) in ten healthy volunteers using positron emission tomography (PET) with [¹⁸F]FE-PE2I, a new PET radioligand with high affinity and selectivity for the dopamine transporter, to characterize its relation to abuse liability. Mean striatal DAT occupancies were 51.4% at 200 mg and 56.9% at 300 mg. There was a significant correlation between occupancy and plasma concentration, indicating dose dependency of DAT inhibition by modafinil in the striatum, and especially in the nucleus accumbens. This study showed that DAT occupancy by modafinil was close to that of methylphenidate, indicating that modafinil may be near the same level as methylphenidate in relation to abuse liability in terms of dopaminergic transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Imaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 2×
“Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (i.e. schizophrenia, attention-deficit/hyperactivity disorder [ADHD]) (Minzenberg and Carter, 2008).”
BackgroundAssessing the abuse potential of methylphenidate in nonhuman and human subjects: a review
Kollins, S. H., MacDonald, E. K., & Rush, C. R. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00464-6 · Cited by 365
Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain.
Varnäs, K., Halldin, C., & Hall, H. (2004) · Human Brain Mapping · doi:10.1002/hbm.20035 · Cited by 332 · cited 2×
“Second, because SERT exists, as does DAT, in the striatum, the binding of [(11)C]cocaine does not precisely reflect the quantity of DAT (Staley et al., 1995; Gurevich and Joyce, 1996; Varnas et al., 2004).”
BackgroundSembower, M. A., Ertischek, M. D., Buchholtz, C., Dasgupta, N., & Schnoll, S. H. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759880 · Cited by 34 · cited 2×
“In general, it is said that abuse of methylphenidate is most common (Kollins et al., 2001; Maher, 2008; Bruggisser et al., 2012; Sembower et al., 2013), and a low risk of abuse by bupropion has been reported (Chevassus et al., 2012).”
Background
Cited by
Tardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00374 · Cited by 91
Karila, L., Leroy, C., Dubol, M., Trichard, C., Mabondo, A., Marill, C., Dubois, A., Bordas, N., Martinot, J.-L., Reynaud, M., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.28 · Cited by 27
Modafinil enhances alerting-related brain activity in attention networks
Ikeda, Y., Funayama, T., Tateno, A., Fukayama, H., Okubo, Y., & Suzuki, H. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4614-9 · Cited by 19
“Taken together, modafinil and methylphenidate may preferentially act on the noradrenergic and dopaminergic systems, respectively, although DAT occupancy and extracellular dopamine level under modafinil andmethylphenidate treatments at clinical doses have appeared similar in positron emission tomography (PET) studies (…”
BackgroundSelf-citationArakawa, R., Tateno, A., Kim, W., Sakayori, T., Ogawa, K., & Okubo, Y. (2016) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2016.03.006 · Cited by 16
Self-citation
Metadata
- Authors
- Kim, W., Tateno, A., Arakawa, R., Sakayori, T., Ikeda, Y., Suzuki, H., & Okubo, Y.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-22
- Volume
- 17
- Issue
- 05
- Pages
- 697-703
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2142666676
- Cited by
- 44
- References
- 6
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I. https://app.cochat.ai/papers/10.1017/s1461145713001612
- The paper
- Kim, W., Tateno, A., Arakawa, R., Sakayori, T., Ikeda, Y., Suzuki, H., & Okubo, Y. (2014). In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [18F]FE-PE2I. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145713001612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.